ClinicaliQ Trial Snapshot
- A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction — Recruiting • Phase III • Cardiology /….
- What is being tested: Finerenone (a non-steroidal mineralocorticoid receptor antagonist) is being evaluated for long-term safety and efficacy when combined with standard heart failure treatment in children and young adults with heart failure and left ventricular systolic dysfunction.
- Patient eligibility overview: The study enrolls children and young adults diagnosed with heart failure with left ventricular systolic dysfunction (LVSD), with eligibility criteria likely including specific age ranges, confirmed LVSD on imaging, and current standard heart failure therapy.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Researchers are looking for a better way to treat children and young adults who have heart failure with left ventricular systolic dysfunction (LVSD). Heart failure with left ventricular systolic dysfunction (LVSD) is a condition where the left side of the heart is weak and struggles to pump blood effectively, leading to symptoms like shortness of breath, fatigue, and poor growth. The study treatment, finerenone (also called BAY94-8862), is under development to treat newborns, children, and young adults with heart failure and LVSD. It works by blocking a protein that contributes…
Eligibility Snapshot
- : * For participants rolling over from randomized controlled trial (RCT): Prior participation in the finerenone Phase 3 study FIORE (21466) and not permanently discontinued from the study intervention prior to the end of treatment (EoT) visit in FIORE. * For newly enrolled infants 5.0 mmol/L for children ≥2 years of age, and >5.3 mmol/L for children
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.